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Clinical Presentation and Natural History of Diabetic Patients That Were Introduced to Dialysis Therapy
Hiroshi Takane ( Department of Nephrology, Saitama Medical School, Moroyama, Saitama 350-0495, Japan )
   The purpose of this study is to retrospectively analyze the clinical characteristics in patients with diabetes 
mellitus that were introduced to dialysis therapy. First, we reviewed 120 cases of end-stage renal failure due to 
diabetic nephropathy that were introduced to dialysis therapy in 1996 and 1997. Presenting features were as 
follows: men, 62.5% ; mean age at introduction, 57±1 years; and mean serum creatinine level, 7.3±0.2 mg/dl. To 
find any clinical characteristics in the population, we divided patients to 3 groups according to age - younger (below 
40 years old:12 patients), senior (more than 65 years : 32 patients) and middle : 76 patients -. In younger age 
group, average aged of 36±1 years old had lower serum creatinine levels (6.1±0.4 mg/dl) (p＜0.05) and greater 
cardio-thoracic ratio (61.1±1.3 %) (p＜0.05) obtained from the chest x-ray film than other two groups. There were 
no significant differences between the middle aged (59±1 years old) and the senior aged group (72±1 years old) 
in the levels of serum creatinine and cardio-thoracic ratio. To further analyze the clinical characteristics in the rest 
of groups, the other 113 patients in 1998 and 1999 who were matched with middle age group in the former study, 
were retrospectively analyzed. The average was 61±2 years old, and men 54%(62/113). The %changes in body 
weight were as follows: 9.5±2.8% (p＜0.05) from teens to 20s and 19.2±3.2% (p＜0.05) from teens to 30s in men. 
Compared to these changes, the %changes in body weight in women were as follows: 9.6±2.1% (p＜0.05) from teens 
to 30s and 18.6±2.4% (p＜0.05) from teens to 40s. The ages of the start of dialysis therapy were 54±2 years old in 
men and 59±3 years old in women and there was a significant difference (p＜0.05). In summary, it is suggested that 
young patients with diabetic nephropathy received dialysis therapy because of hypervolemic symptoms compared 
to elder patients, and the renal deterioration progressed more rapidly in male than in female diabetic nephropathy as 
other renal diseases. From these data, in clinical practice these differences should be borne in mind.
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いては対応のない Student’s  t - test，経時変化は対応の

























透析導入時の年齢が 40歳以上 65歳未満である 2型糖
尿病患者 148例中 113名であった．平均年齢は 56±2





Fig. 2に示した．男性では 10歳代から 30歳代にかけ































Fig. 1. Histogram of the numbers of used antihypertensive agents at the start of receiving dialysis therapy. No significant 
difference was observed in the distribution.
Fig. 3. The gains in body weight from on teens. Body weight 
increased in young age in male, and in older age in female. * 
expresses p＜0.05 vs. female.
Fig. 2. Changes in body weight of dialysis patients with 
diabetic nephropathy. The peak of body weight was on thirties 
in male, and on fourties in female. * and + express p＜0.05 vs. 



































































Fig. 5. Glycemic control on the start of receiving dialysis 
therapy.  Fasting serum glucose level were signifincantly lower 
in male at the start of receiving dialysis therapy. Proportion of 
insulin usage was lower also in male. * expresses p＜0.05 vs. 
female.
Fig. 4. Ages on the events in clinical course. Maximum: Ages 
on maximum body weight. Diag. Diabetes: Ages on diagnosis 
of diabetes mellitus. Diag. DMN: Ages on diagnosis of diabetic 
nephropathy. Start Dialysis: Ages on start of receiving dialysis 
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